Plasma Protein Therapeutic Market Outlook 2031
The Global Plasma Protein Therapeutic Market size was valued at USD 28.20 Billion in 2022 and is likely reach to USD 48.46 Billion by 2031, expanding at a CAGR of 6.2% during the forecast period, 2023–2031. The growth of the market is attributed to the plasma product approval across numerous applications, increased R&D activities, and a significant demand for innovative treatment solutions.
Plasma-derived and recombinant analogue therapies are examples of plasma protein therapeutics. Bleeding disorders, immunological deficiencies, lung disorders, neurological disorders, shock and trauma, liver cirrhosis, and infectious diseases such as tetanus, hepatitis, and rabies are among the diseases that can be treated with plasma protein therapeutics.
Plasma protein therapeutics include immunoglobulin, albumin, coagulation factors, and alpha-1 proteinase inhibitors. Life expectancy has increased as a result of technological breakthroughs, advantageous reimbursement policies, and a better standard of living, contributing to the rise in the senior population.
The market penetration of plasma proteins is predicted to expand as new products with clinical benefits such as better efficacy and easy sample plasma extraction techniques are developed.
Manufacturers are focusing on innovative plasma-derived products for the diagnosis of neuropathic pain, myasthenia gravis, and post-polio syndrome among other neurological diseases. Albumin is also being tested in clinical trials to treat liver illness, malaria, sepsis, and Alzheimer's disease.
Furthermore, the greater doses required for subcutaneous immunoglobulin use are expected to drive the demand in developed economies such as the United States. The annual cost of Subcutaneous Immunoglobulin (SCIG) treatment is around USD 40,000 in the region.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing applications of plasma proteins in the pharmaceutical industry is expected to boost the market growth.
- Growing expenditure in the healthcare industry along with the introduction of new plasma-based therapies is estimated to fuel the market expansion in coming years.
- Increasing demand for plasma-based therapies in emerging economies is attributed to provide the lucrative opportunities for the market players.
- Technology advancement and growing adoption rate of new therapeutics in the sector is expected to accelerate the plasma protein therapeutic market growth.
- Slower approval procedures and implementation of stringent regulation policies regarding plasma protein therapy are anticipated to hamper the market growth.
Scope of Plasma Protein Therapeutic Market Report
The report on the global plasma protein therapeutic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Plasma Protein Therapeutic Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Immunoglobulin, Albumin, and Factor VIII), Applications (Primary Immunodeficiency Disorder, Hemophilia, Idiopathic Thrombocytopenic Purpura, and Others),
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Octapharma AG; CSL Behring LLC; Shire Plc; Grifols S.A.; Biotest AG; Bayer AG; and Kedrion S.P.A.
|
Plasma Protein Therapeutic Market Segment Insights
Albumin segment is expected to expand at a robust pace
Based on products, the plasma protein therapeutic market is segmented immunoglobulin, albumin, and factor VIII. The immunoglobulin segment is expected to account for a key share of the market in the coming years owing to the authorization of biologics for a variety of purposes, the convenience of administration, and the cost of treatment.
However, the albumin segment is anticipated to expand at a rapid pace during the forecast period owing to improved diagnosis of hypoalbuminemia caused by cirrhosis of the liver and hepatitis B. High demand and usage in China, the world's largest market for albumin, are expected to fuel additional expansion.
Meanwhile, the factor VIII segment is projected to register a high CAGR during the forecast period as it is required as a prophylactic or on-demand medication for patients with moderate to severe haemophilia A. Around 70% of haemophilia patients, on the other hand, are receiving no or insufficient treatment.
The replacement therapy Alpha-1 Antitrypsin (AAT) is used to treat a rare form of hereditary emphysema. Chronic obstructive pulmonary disease (COPD), bronchitis, and newborn hepatitis are all symptoms of the protein insufficiency.
Currently, only roughly 10%-15% of AAT deficient individuals in the United States and Europe receive treatment, leaving possibility for the market expansion. Improvements in diagnostic rates and product introductions are expected to foster profitable growth in the entire segment.
PID segment is anticipated to register a substantial CAGR
In terms of applications, the market is segmented into primary immunodeficiency disorder [PID], hemophilia, idiopathic thrombocytopenic purpura [ITP], and others. The PID segment is expected to register a substantial CAGR during the forecast period owing to the increasing expansion of immunoglobulin clinical uses, approval of SCIGs.
Meanwhile, the hemophilia segment is expected to represent a substantial growth rate due to increasing prevalence and rising demand for the diagnosis.
Plasma Protein Therapeutic Market Regional Outlook
Asia Pacific is anticipated to dominate the market
On the basis of regions, the plasma protein therapeutic market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Asia Pacific is anticipated to expand at an impressive CAGR and is likely to dominate the market during the forecast period.
The regional market growth can be attributed to rising demand for efficient treatment alternatives, developing economies, and rising per capita income. These factors are listed to provide growth opportunities for market players in emerging countries.
The market of North America, however, is projected to account for a key share of the market in the coming years owing to large patients’ base, growing geriatric population, and the availability of well-developed infrastructure for storing as well as keeping high-quality source plasma.
Segments
Products
- Immunoglobulin
- Albumin
- Factor VIII
Applications
- Primary Immunodeficiency Disorder (PID)
- Hemophilia
- Idiopathic Thrombocytopenic Purpura (ITP)
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global plasma protein therapeutic market are Octapharma AG; CSL Behring LLC; Shire Plc; Grifols S.A.; Biotest AG; Bayer AG; and Kedrion S.P.A. The immunoglobulin therapy Hizentra, used for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy, was approved by the Food and Drug Administration (FDA) in March 2018.
The company's market supremacy is supported by superiority in China, differentiated product profile, the large number of plasma donor centres, and substantial fractionation capacity.
Request For Customization
Enquiry Before Buying
Speak With Analyst
